| ¿µ¹® | iron deficiency anemia | ÇÑ±Û | ö°áÇ̺óÇ÷ |
|---|---|---|---|
| ¼³¸í | ÀûÇ÷±¸ÀÇ ±â´ÉÀº »ê¼Ò¸¦ ¿î¹ÝÇϴµ¥ ÀÖ´Ù. ÀûÇ÷±¸ ¼Ó¿¡ »ê¼Ò¿Í °áÇÕÀ» ÇÏ¿© »ê¼Ò¸¦ ¿î¹ÝÇÏ´Â Ç÷»ö¼Ò¶ó´Â ¹°ÁúÀÌ ÀÖ´Ù. öÀº ÀÌ Ç÷»ö¼ÒÀÇ Áß¿äÇÑ ºÎºÐÀ» ÀÌ·ç´Â °ÍÀ¸·Î öÀÌ ¾øÀ¸¸é Ç÷»ö¼Ò°¡ ¸¸µé¾îÁú ¼ö°¡ ¾ø´Ù. Ç÷»ö¼Ò°¡ ¾øÀ¸¸é ¿ª½Ã ÀûÇ÷±¸µµ ¸¸µé¾îÁöÁö ¾ÊÀ¸¹Ç·Î ü³»¿¡ öÀÌ ºÎÁ·ÇÏ¸é ºóÇ÷ÀÌ »ý±ä´Ù. ÀÌ Ã¶°áÇ̼º ºóÇ÷Àº ºóÇ÷ÀÇ ¿øÀÎ Áß¿¡¼ °¡Àå ÈçÇÑ °ÍÀÌ´Ù(¾à 25%¸¦ Â÷ÁöÇÑ´Ù). öÀúÀå·®ÀÇ ÀúÇÏ-°áÇÌ, Ç÷ûö³óµµÀÇ ÀúÇÏ, Æ®¶õ½ºÆä¸°·® »ó½Â, Æ®¶õ½ºÆä¸°Æ÷ȵµÀÇ ÀúÇÏ, Ç÷»ö¼Ò³óµµ ¶Ç´Â Ç츶ÅäÅ©¸®Æ®ÀÇ ÀúÇÏ, Àú»ö¼Ò¼º´ëÀûÇ÷±¸¸¦ Ư¡À¸·Î ÇÏ´Â ºóÇ÷·Î¼, »ýü ³»¿¡¼ öÀÌ Àå±â¿¡ °ÉÃÄ °áÇÌµÇ¸ç ±× ¶§¹®¿¡ Ç÷»ö¼Ò »ý»ê °¨¼Ò¿¡ ÀÇÇØ ÀϾÙ. âÀÚ¿¡¼ÀÇ Ã¶Èí¼ö·® ºÎÁ·, öÀÇ ¼ö¿ä Áõ´ë(À¯¾Æ±â, »çÃá±â, ÀÓ½Å), ö¼Ò½Ç°úÀ×(ÃâÇ÷)¿¡ ÀÇÇØ ÀϾ¸ç, ƯÈ÷ »çÃá±â¿¡¼ Æó°æ±â±îÁöÀÇ ¿©¼º¿¡°Ô ¸¹´Ù. Áõ»óÀ¸·Î¼´Â ¾ó±¼Ã¢¹é, ÇǷΰ¨, ÇǺÎâ¹é, ¼ÕÅé º¯È(½ºÇ¬ ¸ð¾ç) µîÀ» ³ªÅ¸³½´Ù. ±¸° ¿µ¿ª¿¡¼´Â ÇôÀÇ Á¢ÃËÅë, ¹ßÀû, °ÇÁ¶°¨, »ïÅ´°ï¶õÀ» ¼ö¹ÝÇϸé Ç÷¯¸Ó-ºó½¼(Plummer-Vinson)ÁõÈıºÀ̶ó°í ÇÑ´Ù. Ç÷¾× ¼Ò°ßÀº Ç÷ûöÀº ÀúÇÏÇϸç, ö°áÇÕ´É·ÂÀÇ »ó½Â, Àú»ö¼Ò¼º ÀÛÀºÀûÇ÷±¸¼ºÀ» ³ªÅ¸³½´Ù. |
||
| ¿µ¹® | multiple sclerosis | ÇÑ±Û | ´Ù¹ß°æÈÁõ |
|---|---|---|---|
| ¼³¸í | ½Å°æÃà»èÀ» µÑ·¯½Î°í ÀÖ´Â ¸»ÀÌÁý(myelin sheath)ÀÇ ÆÄ±«·Î ÀÎÇÑ º´Àû»óŸ¦ ¸»ÇÔ. ÆÄ±«µÈ ¸»ÀÌÁýÀº ÈäÅ͸¦ ³²±â°Ô µÇ¾î ½Å°æÃà»èÀ» ÅëÇÑ ½Å°æÀü´ÞÀÌ Á¦´ë·Î µÇÁö ¾Ê¾Æ ¿îµ¿, °¨°¢, ÀÚÀ²½Å°æ ¸ðµÎÀÇ ½Å°æÀü´ÞÀå¾Ö°¡ ³ªÅ¸³´Ù. ÀÌ º´ÅÍ´Â ¾îµð¼³ª ³ªÅ¸³¯ ¼ö ÀÖ¾î¼ ±× Àå¾Ö°¡ ³ªÅ¸³ª´Â ºÎÀ§¿¡ µû¶ó ¼·Î ´Ù¸¥ Áõ»óÀ» È£¼ÒÇÑ´Ù. |
||
| ¿µ¹® | multiple myeloma | ÇÑ±Û | ´Ù¹ß°ñ¼öÁ¾ |
|---|---|---|---|
| ¼³¸í | ´Ù¹ß¼º ¿ø¹ß¼º°ñÁ¾¾ç. ¸Ó¸®»À-°¥ºñ»À-º¹Àå»À-ôÃß»À-°ñ¹Ý µî¿¡ Àß ³ªÅ¸³ª°í, ¹°··¹°··ÇÑ Á¾±«¸¦ Çü¼ºÇϸç, »ÀÀÇ Èí¼ö°¡ ÀϾ°í, 40~60¼¼ ³²ÀÚ¿¡°Ô ¸¹ÀÌ ¹ß»ýÇÑ´Ù. °ñ¼öÁ¾ Á¾¾ç¼¼Æ÷´Â ÇüÁú¼¼Æ÷¿¡¼ À¯·¡ÇÑ °ÍÀÌ¾î¼ ÇüÁú¼¼Æ÷Á¾À̶ó°íµµ ÇÑ´Ù. °ú°Å¿¡´Â ÇüÁú¼¼Æ÷¼º°ñ¼öÁ¾ À̿ܿ¡´Â ´Ù¸¥ °ñ¼öÁ¶Ç÷¿ä¼Ò¿¡¼ »ý±â´Â °ñ¼öÁ¾À̶ó°í »ý°¢ÇßÁö¸¸ ÇöÀç´Â ºÎÁ¤µÇ°í ÀÖ´Ù. ÇüÁú¼¼Æ÷´Â ¿ø·¡ ¸é¿ª±Û·ÎºÒ¸°À» »ý»êÇÏ´Â ¼¼Æ÷À̸ç, ±×°ÍÀÌ Á¾¾çÈÇÑ ´Ù¹ß °ñ¼öÁ¾ ȯÀÚ¿¡¼µµ ´ëºÎºÐ Ç÷û ¼Ó¿¡ ¸é¿ª ±Û·ÎºÒ¸°ÀÌ Áõ°¡µÈ °ÍÀ» º¼ ¼ö ÀÖ´Ù. Áõ°¡ÇÑ ±Û·ÎºÒ¸°Àº IgG³ª IgAÀÎ °æ¿ì°¡ ¸¹Áö¸¸ ´Ù¸¥ Çüµµ ÀÖ´Ù. °ñ¼öÁ¾ ȯÀÚ ¾à 50%´Â ¿ÀÁÜ¿¡¼ º¥½ºÁÔ½º´Ü¹éÁúÀÌ °ËÃâµÇ´Âµ¥, ÀÌ ´Ü¹éÁúÀÇ ÃàÀû¿¡ ÀÇÇØ ¿ä¼¼°üÀÌ ÆÄ±«µÇ°í, ÄáÆÏ°æÈ°¡ ÀϾÙ. °ñ¼öÁ¾ ȯÀÚ¿¡¼´Â Ç÷û´Ü¹é ÀÌ»óÀ¸·Î °¡²û ¾Æ¹Ð·ÎÀ̵åÁõÀÌ ³ªÅ¸³´Ù. »À X¼± ¼Ò°ßÀ¸·Î¼´Â µµ·Á³½ º´ÅÍ, °ñÀ¶ÇØ»ó, º´Àû°ñÀýÀÌ °üÂûµÈ´Ù. |
||
| ¿µ¹® | multiple personality | ÇÑ±Û | ´ÙÀμº ÀÎ°Ý |
|---|---|---|---|
| ¼³¸í | ÇØ¸®¼º Á¤½ÅÀå¾ÖÀÇ Çϳª·Î ³ªÅ¸³´Ù. ÇÑ »ç¶÷ÀÌ ¿©·¯ »ç¶÷ÀÇ ¼º°ÝÀ» ¼ÒÀ¯Çϰí ÀÖ´Â °ÍÀ¸·Î ¸¶Ä¡ ¡°Áöų¹Ú»ç¿Í ÇÏÀÌµå ¾¾¡±¿Í °°Àº °æ¿ìÀÌ´Ù. ¾Æ¸¶, ÇöÀç ÀÚ½ÅÀÇ Ã³Áö¿¡¼ ¹þ¾î³ª°í ½ÍÀº ¹«ÀǽÄÀûÀÎ ¿å¸Á¿¡¼ ºñ·ÔµÇ´Â °ÍÀ¸·Î ¿©°ÜÁø´Ù. |
||
| MEN | Multiple Endocrine Neoplasia ; AD Trait 1. MEN Type I(= Wermer Syndro... |
|---|---|
| ECG | Electro-Cardio-Graphy(-Gram); ½ÉÀüµµ = EKG 1. Conducting System Structu... |
| MD | Doctor of Medicine [Lat. Medicinae Doctor]; magnesium deficiency; main duct; maintenance dose; major... |
| MEDAC Syndrome | Multiple-Endocrine Deficiency Autoimmune-Candidiasis |
| MEDAC | multiple endocrine deficiency, Addison's disease, and candidiasis [syndrome] |
| MEA | Multiple Endocrine Adenomatosis |
|---|---|
| MEN | Multiple Endocrine Neoplasia |
| MEN I | Multiple Endocrine Neoplasia |
| MEN 1 | Multiple Endocrine Neoplasia Type 1 |
| MEN2a | Multiple Endocrine Neoplasia Type 2a |
| multiple endocrine deficiency syndrome | <syndrome> Acquired deficiency of the function of several endocrine glands, usually on an auto-immune basis. Synonym: multiple glandular deficiency syndrome. (05 Mar 2000) |
|---|
| multiple endocrine adenomatosis | The presence of functioning tumours in more than one endocrine gland, commonly the pancreatic islets and parathyroid glands, which may be associated with Zollinger-Ellison syndrome; dominant inheritance. Synonym: multiple endocrine adenomatosis. (05 Mar 2000) |
|---|---|
| multiple endocrine neoplasia | (type I) This is a hereditary disorder in which two or more of the following glands: parathyroid, pancreas, pituitary, adrenals or thyroid develop hyperplasia or a tumour. (type II) This is a hereditary disorder in which two or more of the following glands: thyroid, adrenal or parathyroid, develop overgrowth (hyperplasia) or malignant cells (cancer). The underlying cause is genetic and a positive family history for this illness is a risk factor. Incidence: approximately 3 in 100,000 people in the general population. Origin: Gr. Plassein = to form (27 Sep 1997) |
| multiple endocrine neoplasia 1 | <radiology> Multiple endrocrine neoplasia syndrome three P's. Pituitary adenoma, 65% can develop Cushing's, acromegaly, prolactinoma, parathyroid hyperplasia / adenoma, 88% can develop hyper-PTH pancreatic isleT-cell tumour, gastrinoma (Z-E) most common, 50% of Z-E can develop MEN-1, inconstant features: bronchial/intestinal carcinoid, thyroid adenoma, adrenal cortical tumour, lipoma, thymoma tissue expression Primary hyperparathyroidism (90%), Gastrinoma (30%), Prolactinoma (15%), Other (10%). Synonym: Wermer syndrome (12 Dec 1998) |
| multiple endocrine neoplasia 2 | <radiology> Multiple endocrine neoplasia syndrome, medullary thyroid carcinoma, usually multifocal; metastasis to local nodes, lung, liver, usually calcify in liver, pheochromocytoma, almost always bilateral, parathyroid hyperplasia, may be secondary to calcitonin secreted by medullary thyroid carcinoma inconstant feature: adrenal cortical hyperplasia Synonym: Sipple syndrome (12 Dec 1998) |
| multiple endocrine neoplasia 3 | <radiology> Multiple endocrine neoplasia syndrome (type 2B, type 3), medullary thyroid carcinoma, pheochromocytoma, marfanoid habitus (Cf: Marfan syndrome), mucosal neuromas, neurofibromas, ganglioneuromatosis coli More info: MEN syndrome 2B Synonym: Schimke, marfanoid syndrome (12 Dec 1998) |
| multiple endocrine neoplasia type 1 | A rare syndrome characterised by hyperplasia and/or neoplasms of the pituitary, parathyroid glands, and pancreatic islets. Hyperparathyroidism occurs in 90% of the cases and is usually the first manifestation of the syndrome. The most frequent pancreatic manifestation is gastrinoma typically leading to zollinger-ellison syndrome. The appearance of this condition has been limited to the loss of allelic heterozygosity at the 11q13 locus on the long arm of chromosome 11. Patients overall exhibit long survival times. Chemotherapy is rare and surgical management is generally dependent on the genetic expression in individual patients. (12 Dec 1998) |
| multiple endocrine neoplasia type 2 | <syndrome> This is a hereditary disorder in which two or more of the following glands: thyroid, adrenal or parathyroid, develop overgrowth (hyperplasia) or malignant cells (cancer). The underlying cause is genetic and a positive family history for this illness is a risk factor. Incidence: approximately 3 in 100,000 people in the general population. (27 Sep 1997) |
| multiple endocrine neoplasia type 2a | A type of multiple endocrine neoplasia characterised by a virtually 100% incidence of medullary thyroid carcinoma, a 50% incidence of pheochromocytoma, and a lesser incidence of parathyroid adenomas associated with hyperparathyroidism. The condition is always transmitted through autosomal dominant inheritance. Genetic testing can identify individuals with the trait in early infancy. Treatment is usually excision of the enlarged parathyroid glands. (12 Dec 1998) |
| multiple endocrine neoplasia type 2b | A type of multiple endocrine neoplasia occurring as an isolated congenital presentation or as a distinct autosomal dominant disease. It is characterised by the 100% incidence of medullary thyroid carcinoma and frequent pheochromocytomas; patients seldom exhibit hyperparathyroidism. It is distinguished from men 2a by its characteristic physical appearance resulting from numerous neural defects including mucosal neuromas of the eyelids, lips, and tongue. The neural abnormalities also include widespread neurogangliomatosis of the gastrointestinal tract leading to abnormal gut motility. Treatment usually requires total thyroidectomy following evaluation for the presence of pheochromocytomas. (12 Dec 1998) |
| familial multiple endocrine adenomatosis | The presence of functioning tumours in more than one endocrine gland, commonly the pancreatic islets and parathyroid glands, which may be associated with Zollinger-Ellison syndrome; dominant inheritance. Synonym: multiple endocrine adenomatosis. (05 Mar 2000) |
| multiple glandular deficiency syndrome | <syndrome> Acquired deficiency of the function of several endocrine glands, usually on an auto-immune basis. Synonym: multiple glandular deficiency syndrome. (05 Mar 2000) |
| multiple carboxylase deficiency | Abnormalities in carbohydrate and branched-chain amino acid catabolism that are responsive to biotin therapy. It may be due to deficiency of propionyl-CoA carboxylase, methylcrotonyl-CoA carboxylase, biotinidase, or propionyl-CoA carboxylase, methylcrotonyl-CoA carboxylase, and pyruvate carboxylase. (12 Dec 1998) |
| multiple sulfatase deficiency | An inherited disorder (autosomal recessive) in which there is a failure to hydrolyze sulfatides and sulfated mucopolysaccharides; this failure leads to their accumulation in neural and extraneural tissues causing demyelination, sulfatiduria, facial and skeletal dysmorphism, etc. (05 Mar 2000) |
| multiple hamartoma syndrome | Hypertrichosis and gingival fibromatosis from infancy, accompanied by postpubertal fibroadenomatous breast enlargement; papules of the face are characteristic of multiple trichilemmomas. Synonym: multiple hamartoma syndrome. (05 Mar 2000) |
| multiple lentigines syndrome | <syndrome> An autosomal dominant inherited disorder characterised by freckle-like spots (lentigines) on the trunk. Other findings may include wide set eyes, sternum abnormalities, prominent ears, deafness, cafe-au-lait spots, pulmonary stenosis, cryptorchidism, delayed puberty or hypogonadism. There is no treatment available only underlying management of each problem. Inheritance: autosomal dominant. (27 Sep 1997) |
Á¦Ç°¸í |
ÆÇ¸Å»ç |
º¸ÇèÄÚµå | ¼ººÐ/ÇÔ·® | ±¸ºÐ/º¸Çè±Þ¿© |
|---|
Á¦Ç°¸í |
ÆÇ¸Å»ç |
º¸ÇèÄÚµå | ¼ººÐ/ÇÔ·® | ±¸ºÐ/º¸Çè±Þ¿© |
|---|